Stockscreener 앱 받기
437.15
0.61%
2.63
시간 외 거래:
437.15
전일 마감가:
$434.52
열려 있는:
$440.02
하루 거래량:
1.26M
Relative Volume:
0.84
시가총액:
$112.08B
수익:
$11.74B
순이익/손실:
$3.68B
주가수익비율:
30.81
EPS:
14.1888
순현금흐름:
$3.34B
1주 성능:
+6.76%
1개월 성능:
+6.05%
6개월 성능:
+3.80%
1년 성능:
-9.67%
1일 변동 폭
$433.67
$442.22
1주일 범위
$410.50
$442.22
52주 변동 폭
$362.50
$519.68
버텍스 파마슈티컬 Stock (VRTX) Company Profile
명칭
Vertex Pharmaceuticals Inc
전화
(617) 341-6393
주소
50 NORTHERN AVENUE, BOSTON, MA
VRTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
버텍스 파마슈티컬 Stock (VRTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-25 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | 개시 | Raymond James | Mkt Perform |
| 2025-08-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-12 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-19 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Perform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 개시 | Redburn Atlantic | Buy |
| 2024-04-11 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-02-06 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-02 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | 다운그레이드 | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-05-04 | 재개 | Piper Sandler | Overweight |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2023-01-17 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-01 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-05-06 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 재확인 | JP Morgan | Overweight |
| 2022-01-27 | 재확인 | Morgan Stanley | Underweight |
| 2022-01-27 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-01-27 | 재확인 | Stifel | Hold |
| 2022-01-27 | 재확인 | Wolfe Research | Outperform |
| 2022-01-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-30 | 개시 | Daiwa Securities | Outperform |
| 2020-11-30 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 개시 | Bernstein | Outperform |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-07-31 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-09-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-08-01 | 다운그레이드 | Needham | Buy → Hold |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | In-line |
| 2019-03-26 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | 다운그레이드 | Maxim Group | Buy → Hold |
모두보기
버텍스 파마슈티컬 주식(VRTX)의 최신 뉴스
Will Vertex Pharmaceuticals Incorporated benefit from macro trends2025 Growth vs Value & Daily Volume Surge Trade Alerts - newser.com
Is Vertex Pharmaceuticals Incorporated stock a smart buy before Fed meetingJuly 2025 Intraday Action & Daily Volume Surge Trade Alerts - newser.com
Visual analytics tools that track Vertex Pharmaceuticals Incorporated performanceQuarterly Risk Review & Weekly Momentum Stock Picks - newser.com
Daiwa Securities Adjusts Price Target on Vertex Pharmaceuticals to $500 From $430, Maintains Buy Rating - MarketScreener
How Vertex Pharmaceuticals Incorporated (VX1) stock moves on employment dataWeekly Profit Summary & Step-by-Step Swing Trade Plans - newser.com
Is Vertex Pharmaceuticals Incorporated (VX1) stock a buy on weaknessPortfolio Update Report & Breakout Confirmation Trade Signals - newser.com
Exit strategy if you’re trapped in Vertex Pharmaceuticals IncorporatedMarket Movement Recap & Verified Technical Signals - newser.com
Evercore ISI Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Published on: 2025-11-13 02:36:05 - newser.com
Vertex Pharmaceuticals Incorporated’s volatility index tracking explained2025 Retail Activity & Real-Time Volume Analysis - newser.com
Published on: 2025-11-12 14:18:38 - newser.com
Novartis, Vertex, More Optimizing Shots on Multiple Goals in Lucrative I&I Space - BioSpace
Vertex Pharmaceuticals’ Promising Cystic Fibrosis Study: A Potential Game-Changer - MSN
Vertex highlights growing Medicaid coverage for non-opioid painkiller Journavx (VRTX:NASDAQ) - Seeking Alpha
Transcript : Vertex Pharmaceuticals Incorporated Presents at UBS Global Healthcare Conference 2025, Nov-09-2025 through Nov-12-2025 - MarketScreener
Barclays Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX) - The Globe and Mail
The Bull Case for Vertex Pharmaceuticals (VRTX) Could Change Following Strong Kidney Data and Regulatory Progress - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alnylam Pharma (ALNY) and Insulet (PODD) - The Globe and Mail
Vertex Pharmaceuticals: Promising Growth in Renal Disease Market with Strong Clinical Data and Strategic Development - TipRanks
Vertex stock holds steady as Stifel maintains $445 price target By Investing.com - Investing.com UK
Vertex Pharmaceuticals’ Promising Renal Franchise Developments Justify Buy Rating - TipRanks
5 Insightful Analyst Questions From Vertex Pharmaceuticals's Q3 Earnings Call - Finviz
Vertex Pharma Q3 2025 Earnings: $3.08B Revenue, EPS $4.80, Updates GuidanceNews and Statistics - IndexBox
Published on: 2025-11-10 02:55:06 - newser.com
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q3 Earnings Call - The Globe and Mail
Can machine learning forecast Vertex Pharmaceuticals Incorporated recoveryJuly 2025 Reactions & Daily Profit Focused Stock Screening - newser.com
Vertex Pharmaceuticals (VRTX) Reports Promising Results from RUB - GuruFocus
Vertex Unveils Positive 48-Week Data For Povetacicept In IgAN And PMN - Nasdaq
Transcript : Vertex Pharmaceuticals IncorporatedSpecial Call - MarketScreener
Vertex reports promising 48-week data for povetacicept in kidney diseases - Investing.com Canada
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week - Business Wire
VRTX: UBS Adjusts Vertex Pharmaceuticals Price Target to $546 | VRTX Stock News - GuruFocus
UBS Adjusts Price Target on Vertex Pharmaceuticals to $546 From $553, Maintains Buy Rating - MarketScreener
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Top Biotech Stocks To Follow TodayNovember 3rd - MarketBeat
Nasdaq, Vertex CEOs talk biotech public markets, AI at Boston event - The Business Journals
Agree To Buy Vertex Pharmaceuticals At $290, Earn 6.5% Using Options - Nasdaq
Why Vertex Pharmaceuticals Incorporated (VX1) stock signals breakout potential2025 Biggest Moves & Community Trade Idea Sharing Platform - newser.com
Evercore ISI Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail
How big funds are accumulating Vertex Pharmaceuticals Incorporated (VX1) stockWeekly Investment Report & Growth Oriented Trading Recommendations - newser.com
버텍스 파마슈티컬 (VRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.21%
1.82%
자본화:
|
볼륨(24시간):